Inventiva Sa Stock Today
| IVA Stock | USD 2.51 0.03 1.21% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Inventiva is trading at 2.51 as of the 17th of February 2025, a 1.21% up since the beginning of the trading day. The stock's open price was 2.48. Inventiva has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of February 2023 and ending today, the 17th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of July 2020 | Category Healthcare | Classification Health Care |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis , mucopolysaccharidoses , and other diseases. Inventiva S.A. was founded in 2011 and is based in Daix, France. The company has 52.36 M outstanding shares of which 355.3 K shares are currently shorted by investors with about 1.59 days to cover. More on Inventiva Sa
Moving together with Inventiva Stock
Moving against Inventiva Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Inventiva Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Old Names | [GUJARAT NRE, Wollongong Coal Limited, INOVA FPO] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, CAC All Shares, NASDAQ Composite, NASDAQ Health Care, CAC All-Tradable, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsInventiva can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Inventiva's financial leverage. It provides some insight into what part of Inventiva's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventiva Sa (IVA) is traded on NASDAQ Exchange in USA. It is located in 50 rue de Dijon, Daix, France, 21121 and employs 123 people. Inventiva is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 229.75 M. Inventiva Sa runs under Biotechnology sector within Health Care industry. The entity has 52.36 M outstanding shares of which 355.3 K shares are currently shorted by investors with about 1.59 days to cover.
Inventiva Sa has about 76.72 M in cash with (81.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.82.
Check Inventiva Probability Of Bankruptcy
Ownership AllocationInventiva Sa has a total of 52.36 Million outstanding shares. Roughly 90.76 (percent) of Inventiva outstanding shares are held by general public with 9.24 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Inventiva Ownership Details
Inventiva Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Yiheng Capital Llc | 2024-12-31 | 2.6 M | |
| Nea Management Company, Llc | 2024-12-31 | 1.5 M | |
| Bvf Inc | 2024-12-31 | 686 K | |
| Commonwealth Equity Services Inc | 2024-12-31 | 42 K | |
| Susquehanna International Group, Llp | 2024-09-30 | 16.3 K | |
| Bnp Paribas Arbitrage, Sa | 2024-12-31 | 1.9 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.4 K | |
| Covestor Ltd | 2024-09-30 | 337 | |
| Ubs Group Ag | 2024-09-30 | 0.0 |
Inventiva Historical Income Statement
Inventiva Stock Against Markets
Inventiva Corporate Management
| Jean Volatier | Chief Officer | Profile | |
| Eric LLM | General Counsel | Profile | |
| Pascaline Clerc | Executive Affairs | Profile | |
| Alice PharmD | Chief Officer | Profile | |
| Frederic Cren | CEO CoFounder | Profile | |
| JeanPaul MD | Head Pharmacovigilance | Profile | |
| Michael Cooreman | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inventiva Sa. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inventiva. If investors know Inventiva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inventiva listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.14) | Revenue Per Share | Quarterly Revenue Growth (0.59) | Return On Assets | Return On Equity |
The market value of Inventiva Sa is measured differently than its book value, which is the value of Inventiva that is recorded on the company's balance sheet. Investors also form their own opinion of Inventiva's value that differs from its market value or its book value, called intrinsic value, which is Inventiva's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inventiva's market value can be influenced by many factors that don't directly affect Inventiva's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inventiva's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inventiva is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inventiva's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.